Rhee Connie M, Ayus Juan Carlos, Kalantar-Zadeh Kamyar
Harold Simmons Center for Kidney Disease Research and Epidemiology, Division of Nephrology and Hypertension, University of California Irvine, Orange, California, USA.
Renal Consultants of Houston, Houston, Texas, USA.
Kidney Int Rep. 2019 Mar 1;4(6):769-780. doi: 10.1016/j.ekir.2019.02.012. eCollection 2019 Jun.
Sodium derangements are among the most frequently encountered electrolyte disorders in patients with end-stage renal disease. As dialysis patients are predisposed to hyponatremia via multiple pathways, assessment of extracellular volume status is an essential first step in disentangling potential etiologic factors. In addition, multiple large population-based studies indicate that proxies of malnutrition (e.g., low body mass index, serum albumin, and serum creatinine levels) and loss of residual kidney function are important determinants of hyponatremia in dialysis patients. Among hemodialysis and peritoneal dialysis patients, evidence suggests that incrementally lower sodium levels are associated with increasingly higher death risk, highlighting the long-term risk of hyponatremia. Whereas in conventional survival models incrementally lower serum sodium concentrations are associated with worse mortality in hemodialysis patients, studies that have examined repeated measures of predialysis sodium have demonstrated mixed associations of time-varying sodium with higher mortality risk (i.e., U-shaped vs. inverse linear relationships). Although the causality of the hyponatremia-mortality association in dialysis patients remains uncertain, there are several plausible pathways by which lower sodium levels may lead to higher death risk, including central nervous system toxicity, falls and fractures, infection-related complications, and impaired cardiac function. Areas of uncertainty ripe for future studies include the following: (i) mechanistic pathways by which lower serum sodium levels are linked with higher mortality in dialysis patients, (ii) whether correction of sodium derangements improves outcomes, (iii) the optimal sodium target, and (iv) the impact of age and other sociodemographic factors on hyponatremia-outcome associations.
钠紊乱是终末期肾病患者中最常见的电解质紊乱之一。由于透析患者通过多种途径易发生低钠血症,评估细胞外液容量状态是理清潜在病因的关键第一步。此外,多项基于大人群的研究表明,营养不良的指标(如低体重指数、血清白蛋白和血清肌酐水平)以及残余肾功能丧失是透析患者低钠血症的重要决定因素。在血液透析和腹膜透析患者中,有证据表明钠水平逐渐降低与死亡风险逐渐升高相关,这突出了低钠血症的长期风险。在传统生存模型中,血液透析患者血清钠浓度逐渐降低与死亡率升高相关,但研究重复测量透析前钠水平时,发现随时间变化的钠与较高死亡风险之间的关联不一(即U形与负线性关系)。虽然透析患者低钠血症与死亡率之间的因果关系仍不确定,但有几种合理的途径可使较低钠水平导致较高死亡风险,包括中枢神经系统毒性、跌倒和骨折、感染相关并发症以及心功能受损。未来研究的不确定领域包括:(i)较低血清钠水平与透析患者较高死亡率相关的机制途径;(ii)纠正钠紊乱是否能改善预后;(iii)最佳钠目标;(iv)年龄和其他社会人口学因素对低钠血症与预后关联的影响。